VRXA — Veraxa Biotech Holding AG stock price, charts and financials

QT—Veraxa Biotech Holding AG

Veraxa Biotech Holding AG (NASDAQ: VRXA) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
1.46
-0.01-0.68%
OverviewShort InterestFilings
VRXAVeraxa Biotech Holding AG·NASDAQ
1.46-0.68%
TA
Loading chart...
Screen all →
RAPP-3.58%$40.45GHRS-1.60%$28.26AGIO-1.61%$33.07ZBIO-1.47%$31.50ADMA+1.79%$9.11VCEL-0.03%$40.02RXRX+8.19%$3.83KOD-0.43%$32.71
Snapshot
Index-P/E-EPS (ttm)-Insider Own-Shs Outstand141.41MPerf Week-11.52%
Market Cap206.46MForward P/E-EPS next Y-Insider Trans-Shs Float12.61MPerf Month-21.51%
Enterprise Value-PEG-EPS next Q-Inst Own-Short Float0.14%Perf Quarter-67.41%
Income-P/S-EPS this Y-Inst Trans-Short Ratio0.42Perf Half Y-
Sales-P/B-EPS next Y-ROA-Short Interest202.96KPerf YTD-89.57%
Book/sh-P/C-EPS next 5Y-ROE-52W High27.34 -94.66%Perf Year-
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-52W Low1.27 14.96%Perf 3Y-
Dividend Est.-EV/EBITDA-Sales past 3/5Y-Gross Margin-Volatility6.97% 11.04%Perf 5Y-
Dividend TTM-EV/Sales-EPS Y/Y TTM-Oper. Margin-ATR (14)0.20Perf 10Y-
Dividend Ex-Date-Quick Ratio-Sales Y/Y TTM-Profit Margin-RSI (14)37.90Recom-
Dividend Gr. 3/5Y-Current Ratio-EPS Q/Q-SMA20-6.98%Beta3.77Target Price-
Payout-Debt/Eq-Sales Q/Q-SMA50-18.77%Rel Volume0.03Prev Close1.47
Employees8LT Debt/Eq-Earnings-SMA200-57.24%Avg Volume542.23KPrice1.46
IPO DateJun 09, 2026Option/ShortNo / YesEPS/Sales Surpr.-Net Debt/EBITDA-Volume16,375Change-0.68%
Latest News· Times ET
Sep-16-26
Sep-16-2603:00PM
VERAXA Biotech (VRXA) Building a New Approach to Precision Cancer TherapyYahoo
Sep-09-26
Sep-09-2611:46AM
VERAXA Biotech Designates Raju Willener as CFOYahoo
Sep-04-26
Sep-04-2612:30PM
These stocks are moving in today's sessionChartMill
03:00AM
VERAXA Biotech Appoints Raju Willener as Chief Financial Officerglobenewswire.com
Aug-24-26
Aug-24-2603:10AM
VERAXA Biotech Announces Initial Results From Strategic Research Collaboration To Develop Next-Generation Antibody Oligonucleotide Conjugates For Autoimmune And Chronic Immune Diseases; In Early In Vitro Studies, An AOC Candidate Demonstrated Greater PotencyBenzinga
Jul-31-26
Jul-31-2601:17PM
Veraxa Biotech Files Prospectus Related To The Resale Of Up To 25M Ordinary Shares By The Selling ShareholderBenzinga
Jul-29-26
Jul-29-2603:00AM
VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidatesglobenewswire.com
Jul-27-26
Jul-27-2603:07AM
VERAXA Biotech Advances Bispecific ADC VXA‑222 With OmniAb Milestone, Moving Alliance Into Next Phase Of Cancer Therapy DiscoveryBenzinga
03:00AM
VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAbglobenewswire.com
Jul-24-26
Jul-24-2612:05PM
VERAXA Biotech Shareholders Approve All Proposals at Extraordinary General Meeting, Strengthening Strategic Flexibility for Future Growthglobenewswire.com
Jul-23-26
Jul-23-2603:00AM
VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC® Technology Platforms and Portfolioglobenewswire.com
Jul-20-26
Jul-20-2603:09AM
VERAXA Gets German Regulatory Feedback On Cancer Therapy PlanBenzinga
03:00AM
VERAXA Biotech Announces Regulatory Progress with its BiTAC®-TCE Development Planglobenewswire.com
Jul-13-26
Jul-13-2603:08AM
VERAXA Biotech Partners With AI-Driven Computational R&D Partner Ardigen To Support Its Growing BiTAC Pipeline Of T Cell Engagers And Antibody Drug ConjugatesBenzinga
03:00AM
VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipelineglobenewswire.com
Company

Veraxa Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partnership models for collaborative development from target identification to antibody and ADC creation. The company was founded in 2021 and is based in Heidelberg, Germany.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.